GE HealthCare Unveils Logiq Totus Ultrasound at ECR
Designed for full-body imaging, the new modality reportedly offers a lightweight portable design, AI-powered tools and enhanced high-resolution images.
Emphasizing a combination of workflow enhancements and advances to facilitate improved image quality, GE HealthCare has launched the Logiq Totus ultrasound system at the European Congress of Radiology.
Use of the Logiq Totus ultrasound system enables access to a wide range of transducers to help foster high resolution for a variety of areas, advanced tools such as 2D Shear Wave Elastography and access to cSound™ Architecture, which provides enhanced consistent image quality, according to GE HealthCare.
GE HealthCare said the Logiq Totus ultrasound system, launched at the European Congress of Radiology, offers a combination of workflow enhancements and advances to facilitate improved image quality. (Image courtesy of GE HealthCare.)
The company said other advantages with the lightweight, portable system include tools such as Scan Assistant and Voice Control that help streamline workflows, and access to Breast and Thyroid Assistant artificial intelligence (AI) support tools from Koios Medical.
“ … We’re focused on driving innovation that enables precision care, and the enhanced (Logiq) portfolio allows us to deliver on this promise with products and solutions that help clinicians optimize care with ease and efficiency,” said Jyoti Gera, the general manager of General Imaging and Primary Care, Ultrasound at GE HealthCare.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
